Comprehensive Stroke Center
National Association of Epilepsy Center
Certified ALS Center Program
AANEM EDX Lab Accreditation

DC Epilepsy Diagnosis & Treatment

We Treat More Than 2000 Patients With Epilepsy Every Year

Epilepsy has many possible causes, and can be related to other diseases. Seizures can result from brain infections, tumors, abnormal blood vessels, head trauma, and stroke. Still, in many individuals, no clear cause of seizures can be determined.

A multi-disciplinary staff distinguishes The Epilepsy Center from other facilities in the region. Each year, more than 2,000 patients with epilepsy and other seizure disorders travel from around the corner and around the world for comprehensive evaluation and treatment by members of our medical team.

Neurologists, neuroradiologists, neurosurgeons, neuropsychiatrists, nurses, rehabilitation specialists and social workers collaborate to develop a specific treatment program for each patient, whether medication or surgery is indicated. We use electroencephalography (EEG) as well, to measure brain waves that tell us about conditions as diverse as seizures and sleep disorders. We offer outpatient EEG as well as inpatient video-EEG monitoring.

Click here to learn more about our Epilepsy Center.

22nd & I Street, NW
7th Floor
Washington, DC 20037

(202) 741-2700

More Information
1625 N. George Mason Drive
Medical Offices A, Suite 344
Arlington, VA 22205

(703) 842-4180

More Information

Clinical Trials

Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)

This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS

Read More
Food as Medicine to Improve Lifestyle for Stroke Patients (FAMILY (CAFB))

The purpose of this study is to evaluate if groceries delivered every two weeks, along with nutrition education and nutrition counseling, will improve the health of individuals who have recently had a stroke.

Read More
Sleep for Stroke Management And Recovery Trial (SleepSmart)

Investigator-initiated, phase 3 multicenter, prospective randomized open-, blinded-endpoint (PROBE) controlled trial to test whether treatment of obstructive sleep apnea (OSA) with continuous positive airway pressure is effective for secondary prevention and recovery after stroke.

Read More
Preventative treatment of migraine: Outcomes for patients in realy-world healthcare systems (Triumph)

This study is a 24-month prospective, multicenter, international, 2-stage noninterventional study reflecting treatment within real-world settings of patients with migraine who are switching or initiating pharmacologic treatment for migraine prevention

Read More
A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (TV48125)

A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice

Read More
A 12 month prospective, randomized, interventional, global, multicenter, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (AMG334A2401)

This study uses a single-cohort, 2-treatment arm (erenumab versus oral SoC prophylactic treatment), parallel-group randomized (2:1 [erenumab (70mg or 140mg): SoC oral prophylactic]), open-label design in adult patients with episodic migraine who have previously failed 1 or 2 prophylactic migraine treatments.

Read More
A phase 4, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in adults with chronic migraine and medication overuse headache (Amgen20170703)

Study 20170703 is a phase 4, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study to evaluate the safety and efficacy of erenumab against placebo in a CM population with MOH and prior history of treatment failure.

Read More
A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety and tolerability of atogepant for the prevention of chronic migraine (Allergan3101-303-002)

Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of atogepant 30 mg twice per day (BID) and 60 mg once daily for the prevention of chronic migraine (CM).

Read More
A phase 2, randomized, placebo-controlled study to evaluate the safety, tolerability and efficacy of TAK-079 in patients with generalized myasthenia gravis (TAK079-1005)

This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of TAK-079 in patients with generalized MG in combination with standard background therapy.

Read More
A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX

Read More
A phase II study to evaluate the safety and tolerability of pyridostigmine when given with ondansetron to subjets with anti-AChR postive myasthenia gravis (DAS-MG)

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis to compare the gastrointestinal (GI) side effects of pyridostigmine alone and when given with ondansetron in patients with a known diagnosis of anti-AchR antibody positive myasthenia gravis and current (i.e., past 7 days) pyridostigmine-related GI side effects

Read More
A phase 3, multicenter, open-label extension study of Zilucoplan in subjects with generalized myasthenia gravis (RA Pharma 302: Raise XT)

Study RA101495-02.302 is a multicenter, open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study. The visit schedule during the first 12 weeks of Study RA101495-02.302 (RAISE)

Read More

View All Clinical Trials